# Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis.

> **NCT05725876** · PHASE1 · RECRUITING · sponsor: **University Medical Center Groningen** · enrollment: 56 (estimated)

## Conditions studied

- Psoriasis
- Crohn Disease

## Interventions

- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT05725876
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-06
- **Primary completion:** 2026-07-01
- **Final completion:** 2027-01-06
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05725876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05725876, "Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05725876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*